LVS — Las Vegas Sands Corp.

The tape says it plainly: as of 2026-09-13 LVS closed at $42.83, essentially on its 52-week low, with RSI at 35.22 and the price 4.85% below its 20-day SMA, 6.54% below its 50-day, and 20.39% below its 200-day. The catalyst was the July 22, 2026 Q2 print: revenue of $3.15B was roughly flat YoY and diluted EPS of $0.53 badly missed the ~$0.79 consensus, with management and analysts attributing the gap to low VIP hold in rolling play rather than weak mass demand. Multiple covering firms trimmed price targets after that print, and the stock has bled -3.47% in a week, -6.24% in a month, -15.47% in three months. Sentiment is bearish despite a consensus Buy rating and a $59.78 average target, because the market is not paying for a 'luck factor' explanation it has heard before.

The three-year arc is a genuine recovery that hit an air pocket, not (yet) a structural rollover. Revenue climbed from ~$2.7-2.9B per quarter through 2023-2024 to a $3.65B peak in Q4 2025, with YoY growth of +15.0% (Q2 2025), +24.2% (Q3 2025), +26.0% (Q4 2025) and +25.3% (Q1 2026) - a real acceleration. Then Q2 2026 revenue fell to $3.154B, -0.7% YoY, and the first negative YoY revenue print since Q1 2025. Operating margin followed the same shape: 18.8% in Q3 2024, 25.2% in Q2 2025, 23.8% Q3 2025, 24.0% Q4 2025, 25.6% Q1 2026, then 19.6% in Q2 2026 - a 560bp YoY compression in one quarter. EPS swung $0.66 (Q2 2025) to $0.85 (Q1 2026) to $0.53 (Q2 2026). Operating cash flow is comparably volatile ($178M in Q2 2025 vs $1.204B in Q4 2025 vs $692M in Q2 2026), which is the signature of hold-driven casino economics rather than a demand collapse. The honest read: three strong quarters, one bad one, and the company's own explanation (low VIP hold, plus minor World Cup tourism disruption) is plausible but unverified until Q3 2026 reports.

Cheap, with real caveats. As of 2026-09-13, the $42.83 price puts LVS at 16.6x TTM EPS of $2.654 and just 13.8x the $3.104 next-FY consensus EPS, with a PEG of 0.548 - all well below the stated 5-year average P/E of 26.14, though that historical average is inflated by COVID-era depressed Macao earnings and is not a trustworthy anchor. P/S of 2.02 versus a 5-year average of 5.23 looks dramatic but is similarly distorted by 2021-2022 near-shutdown revenue. EV/EBITDA of 8.72 and a TTM FCF yield of 10.0% ($2.788B FCF on a $27.74B market cap) are the cleanest signals, and both say cheap. The dividend yields 2.50% on a payout that uses roughly 40% of EPS and far less of free cash flow. The offsetting negative: P/B of 48.7 is not an overvaluation signal at all - it is an artifact of stockholders' equity having shrunk from $4.118B (Q4 2023) to just $581M (Q2 2026) through buybacks, which removes any book-value floor under the shares.

The stock is pricing in a meaningfully worse future than the sell side models. Consensus sees $3.104 next-FY EPS and a $59.78 target (~40% upside from $42.83), while the market pays only 13.8x those forward numbers and has pushed the shares below every moving average. That gap is the whole trade: either Q2 2026 was a hold-driven one-off and the market is mispricing roughly $0.25-0.30 of normalized quarterly EPS, or Macao mass and premium-mass volumes are quietly softening and the low multiple is correct. The tell is the Q3 2026 print in late October 2026 - you want revenue back above ~$3.4B and operating margin back above ~23%. If Q3 comes in flat-to-down again with margins stuck near 20%, stop calling it a hold problem. Until then, the estimate cuts already made by multiple banks show the Street is not fully defending its own target.

Unambiguously bearish and not yet at a washout. As of 2026-09-13, RSI(14) stood at 35.22 - weak, but above the 30 oversold threshold, so there is no capitulation signal to buy. Price was 4.85% under the 20-day SMA, 6.54% under the 50-day, and 20.39% under the 200-day; the 52-week low of $42.11 sits within 2% of the $42.83 close. Returns of -3.47% (1wk), -6.24% (1mo), -15.47% (3mo) and -20.21% (6mo) describe a persistent, orderly downtrend rather than a bottoming range. Entry-timing implication: there is no technical case to step in here. A first constructive signal would be RSI reclaiming 50 and price reclaiming the 50-day SMA (roughly $45.8 at the time of writing); a weekly close below $42.11 opens the low-$40s/high-$30s with no visible support from the chart.

• Mainland China consumer confidence and macro growth - Macao mass and premium-mass gaming volumes are the direct derivative, and choppy mainland spending is the single biggest swing factor.
• Macao regulatory and concession environment - the six operators, including Sands China, hold concessions running to 2032, but AML scrutiny, visa/policy changes and any increase in concession obligations are live risks.
• Asian cross-border travel normalization - Singapore's Marina Bay Sands is running at record profitability on premium-mass demand, while Macao's recovery remains uneven and sensitive to travel friction.
• Interest rates and the ~$15.26B total debt stack - net debt of roughly $11.9B is about 2.6x TTM EBITDA, manageable, but the multi-billion-dollar MBS expansion phase keeps the capital expenditure cycle heavy.
• China-exposed consumer discretionary sector rotation - the market has been actively de-rating Asia-levered consumer names, which mechanically pressures the multiple irrespective of quarterly results.

• Q3 2026 earnings (tentatively late October 2026) - the single most important datapoint: does Macao VIP hold normalize, and does operating margin recover toward 23-25%? Golden Week commentary will frame the China demand picture.
• Execution pace on the expanded $6.0B share repurchase authorization - LVS bought back $787M of stock in Q2 2026 alone, and continued aggressive repurchases at these prices are a tangible per-share EPS tailwind.
• Progress on Marina Bay Sands expansion and the ongoing Venetian/Londoner Macao suite renovation pipeline - these are the medium-term margin drivers that could re-anchor the multiple.
• Monthly Macao gross gaming revenue prints - high-frequency evidence either confirming or refuting the 'hold, not demand' explanation.
• Potential dividend increase - a 2.50% yield covered by both EPS and free cash flow leaves room for a raise that would broaden the shareholder base.

• The Q2 2026 shortfall is not a hold artifact but the start of genuine Macao mass-market softness - if revenue is flat again in Q3 2026 with margins near 20%, the 13.8x forward P/E is deserved, not cheap.
• VIP hold volatility cuts both ways and makes quarterly earnings structurally unpredictable - Q2 2025 operating cash flow of $178M versus Q4 2025's $1.204B shows how violent the swings are.
• Balance-sheet cushion is nearly gone: stockholders' equity of just $581M as of 2026-06-30, negative working capital (current ratio 0.997), and ~$11.9B of net debt against ~$4.5B TTM EBITDA.
• China policy and regulatory risk - travel restrictions, capital controls, AML tightening, or an adverse change in Macao concession terms would hit revenue and the multiple simultaneously.
• Rising capital intensity: Q2 2026 capex jumped to $332M from $154M in Q3 2025, and the MBS expansion will keep free cash flow conversion below the 10% TTM FCF yield that makes the stock look cheap today.
• Momentum and technical breakdown - trading below all major moving averages near a 52-week low, with no valuation floor from book value, means forced/quantitative selling can extend the decline independent of fundamentals.

LVS is a genuinely cheap asset - 13.8x forward earnings, 8.7x EV/EBITDA, a 10% trailing free cash flow yield and a 2.5% dividend - attached to what is arguably the best casino footprint on earth: a Singapore monopoly at record profitability and the largest mass-market position in Macao. The problem is that the trailing evidence the market is reacting to is real, not imaginary: Q2 2026 revenue was flat YoY, operating margin compressed 560bp, and the equity base has been reduced to $581M. I would not buy this on the current tape. The Q2 miss is more likely a low-hold artifact than demand decay, but 'more likely' is not proof, and the stock offers no technical or balance-sheet support if I'm wrong. Wait for the late-October 2026 Q3 print to confirm revenue above ~$3.4B and margins back above 23%; if that arrives, this re-rates toward my $55 fair value quickly. If it doesn't, $42 is a fair price for a business that is deteriorating.

Primary method: 10.5x EV/EBITDA on ~$4.7B of normalized forward EBITDA (TTM EBITDA of ~$4.54B is derived from the given 8.72x EV/EBITDA and ~$11.9B net debt; I add a modest hold-normalization/MBS ramp), giving ~$49.4B EV less $11.9B net debt = ~$37.4B equity, or ~$58/share on ~648M shares. Cross-checks pull the figure down to a central ~$55: 17x forward EPS of $3.104 (~$53) and an 8.5% required FCF yield on $2.79B TTM FCF (~$51), with the discount to the EV/EBITDA leg reflecting China macro risk and the imminent MBS capex cycle.